Literature DB >> 1934174

Interaction of recombinant human interferon-gamma with liposomes.

H Ishihara1, T Hara, Y Aramaki, S Tsuchiya, K Hosoi.   

Abstract

The interaction of recombinant human interferon-gamma (IFN) with egg phosphatidylcholine liposomes was studied. IFN which binds to liposomes was dependent on the liposomal charge and pH, and a preferential binding was observed in negatively charged liposomes at pH 7.4-10. Electron-microscopic observation showed that the increased liposomal turbidity induced by IFN was due to liposomal aggregation, and the increased turbidity could be decreased by the addition of NaCl. Thus, ionic binding may participate in this interaction. But, when the incubation time was longer, the liposomal aggregation was not decreased by the addition of NaCl, and the leakage of the entrapped marker, calcein, was observed. Electron-microscopic analysis showed that this leakage resulted from the morphological change of liposomes. From these findings, ionic binding may participate in the interaction between IFN and liposomes and then develop a morphological change in negatively charged liposomes under the neutral pH condition.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934174     DOI: 10.1248/cpb.39.1536

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

1.  The contribution of a serum component(s) modified by B cells to the mechanism for macrophage activation by liposomes.

Authors:  Y Aramaki; M Murai; S Tsuchiya
Journal:  Immunology       Date:  1993-10       Impact factor: 7.397

Review 2.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

3.  Activation of Fc receptor-mediated phagocytosis by mouse peritoneal macrophages following the intraperitoneal administration of liposomes.

Authors:  Y Aramaki; M Murai; S Tsuchiya
Journal:  Pharm Res       Date:  1994-04       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.